BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP
May 2 Ablynx Nv:
* Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
* A total of 145 patients have been enrolled
* Data from this Phase III study will be reported in second half of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)